Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study.

Patricia J Rodriguez¹, Jay B Lusk^2,3, Hemalkumar B Mehta⁴, Joseph F Levy⁵, Andreas P Kalogeropoulos⁶, Samir Soneji⁷, Duy Do¹, Emma Holler¹, Emily Webber¹, Ty Gluckman⁸, Nicholas Stucky¹

¹Truveta Inc, Bellevue, Washington, USA.

²Department of Family Medicine, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA.

³Department of Neurology, Duke University, Durham, North Carolina, USA.

⁴Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA hbmehta@jhu.edu.

⁵Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

⁶Stony Brook Heart Institute, Stony Brook University Hospital, Stony Brook, New York, USA.

⁷Department of Population Health Sciences, Duke University, Durham, North Carolina, USA.

⁸Center for Cardiovascular Analytics, Research, and Data Science (CARDS), Providence Heart Institute, Portland, Oregon, USA.

PubMed DOI

Abstract

OBJECTIVE: To evaluate the association between use of newer glucagon-like peptide-1 receptor agonists (GLP-1 RAs; semaglutide, tirzepatide) and alcohol-related hospitalisations among adults with alcohol use disorder (AUD) and type 2 diabetes (T2D) or obesity.Retrospective cohort study using target trial emulation. SETTING: Electronic health record data from a collective of US healthcare systems.…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.